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Abstract
Background
Alternative splicing of the locus AβH-J-J generates functionally distinct proteins: the enzyme
aspartyl (asparaginyl) β-hydroxylase (AAH), truncated homologs of AAH with a role in
calcium homeostasis humbug and junctate and a structural protein of the sarcoplasmic
reticulum membranes junctin. AAH and humbug are over expressed in a broad range of
malignant neoplasms. We have previously reported that this locus contains two promoters, P1
and P2. While AAH and humbug are expressed in most tissues under the regulation of the P1
promoter, AAH, junctin and junctate are predominantly expressed in excitable tissues under the
control of the P2 promoter. We previously demonstrated that Sp transcription factors positively
regulate the P1 promoter.
Results
In the present study, we extended the functional characterization of the P1 promoter of the
AβH-J-J locus. We demonstrated by quantitative Real-time RT-PCR that mRNAs from the P1
promoter are actively transcribed in all the human cell lines analysed. To investigate the
transcription mechanism we transiently transfected HeLa cells with sequentially deleted
reporter constructs containing different regions of the -661/+81 P1 nucleotide sequence. Our
results showed that (i) this promoter fragment is a powerful activator of the reporter gene in
HeLa cell line, (ii) the region spanning 512 bp upstream of the transcription start site exhibits
maximal level of transcriptional activity, (iii) progressive deletions from -512 gradually reduce
reporter expression.
The region responsible for maximal transcription contains an E-box site; we characterized the
molecular interactions between USF1/2 with this E-box element by electrophoretic mobility
shift assay and supershift analysis. In addition, our USF1 and USF2 chromatin
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immunoprecipitation results demonstrate that these transcription factors bind the P1 promoter
in vivo.
A functional role of USF1/USF2 in upregulating P1-directed transcription was demonstrated by
analysis of the effects of (i) in vitro mutagenesis of the P1/E-box binding site, (ii) RNA
interference targeting USF1 transcripts.
Conclusions
Our results suggest that USF factors positively regulate the core of P1 promoter, and, together
with our previously data, we can conclude that both Sp and USF DNA interaction and
transcription activity are involved in the P1 promoter dependent expression of AAH and
humbug.
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Background
We have previously characterized the human AβH-J-J locus, a genomic sequence which
generates functionally distinct proteins [1], including the enzyme aspartyl (asparaginyl) β-
hydroxylase (AAH), junctin, a structural protein of sarcoplasmic reticulum, humbug and
junctate, the truncated homologs of AAH calcium binding proteins [1,2]. AAH catalyzes
posttranslational hydroxylation of aspartate and asparagine residues in certain epidermal
growth factor-like domains present in a number of proteins, such as receptors and receptor
ligands, involved in cell growth and differentiation, and extracellular matrix molecules [3].
AAH, mediates cell motility and invasiveness, an effect which is of interest because of its role
in placental implantation and “receptivity” of endometrium [4]. Humbug is a truncated
homolog of AAH that lacks a catalytic domain. Overexpression of humbug increases
intracellular calcium levels by promoting its release from intracellular stores [5]. The levels of
humbug immunoreactivity are directly associated with colon cancer tumor grade and inversely
associated with patient survival [6]. AAH and/or humbug are over expressed in infiltrative
intrahepatic cholangiocarcinomas, metastasized lung, breast, colon, hepatocellular carcinomas,
and malignant neuroectodermal tumors [7-11]. These proteins can contribute to the malignant
phenotype by increasing motility and enhancing proliferation, survival, and cell cycle
progression. Inhibition of AAH and humbug expression could represent an attractive approach
for gene therapy of infiltrating tumors [3,11].
Junctate is an integral calcium binding protein of sarco(endo)plasmic reticulum membrane,
which forms a supramolecular complex with the inositol 1,4,5 trisphosphate receptor and
modulates calcium entry through receptor- and store-activated channels [1,12,13].
Our group previously reported the identification of two promoter sequences, present within the
human AβH-J-J locus (named P1 and P2), that are expected to regulate the transcription of this
locus [1,14, 15]. The generated primary transcripts undergo alternative splicing and direct the
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synthesis of AAH, humbug, junctin, and junctate. We have previously reported the
characterization of the P2 promoter, demonstrating that the myocyte enhancer factor 2 (MEF-2)
transcription factor binds to this promoter sequence and drives tissue-specific expression, being
responsible of inducing transcription during muscle differentiation [14,15].
In additon, we have recently reported the role of Sp factors in upregulating the P1-directed
transcription of the AβH-J-J locus [16]. This was the first study about the role of the P1
promoter.
In the present study we focused our attention on the role of another putative regulating
sequence, namely an E-box, which is located in the region of the P1 promoter and is required
for high-level of transcription.
To characterize the expression directed by the P1 promoter, we have analysed the
corresponding mRNAs in different cell lines. Furthermore, transfections of HeLa cells with
progressively deleted reporter constructs of the -661/+81 P1 promoter region were performed
and the transcription activity of each fragment was characterized. DNA/transcription factor
interaction studies were performed in vitro by EMSA or supershift assays, and in intact cells by
chromatin immunoprecipitations. Functional assays were performed by in vitro mutagenesis of
the E-box binding site and by RNA interference targeting USF1 [17].
Results
Structure of the 5' end of the AβH-J-J locus.
Figure 1 shows the structure of the 5’ end of the human AβH-J-J locus and the transcripts
for AAH, humbug, junctate and junctin, with the location of the P1 and P2 promoters.
Figure 2 shows the quantitative Real-time RT-PCR analysis of the transcripts starting from
P1 promoter in a panel of human cell lines. In this experiment cDNA derived from MCF7,
Colo 38, Hek293, HepG2, HeLa, RD and MDA human cell lines were employed. The
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results obtained indicate that the P1 promoter directs transcription in all the cell lines
analysed and is more active in HeLa cells (Figure 2, column e). These data confirm and
further extend the concept that P1 promoter, unlike the tissue-specific P2 promoter, directs
transcription in cells of different tissues, as recently reported by our research group
[15,16].
Identification of functional region within the AβH-J-J P1 promoter.
In order to identify putative regulatory regions located within AβH-J-J P1 promoter, HeLa cells
were transiently transfected with sequentially deleted reporter constructs, containing different
regions of the -661/+81 P1 nucleotide sequence cloned into pGL3-basic reporter vector [16].
The data of transient transfection and luciferase assays were normalized to renilla
luciferase activity. An additional comparison was done with the pGL3-basic reporter
vector. The results represented in Fig 3 demonstrate that: i) the -661/+81 promoter region
exhibits high reporter gene expression in HeLa cells; ii) luciferase activity is higher with
the reporter construct lacking the -634/-512 sequence, suggesting the presence in this
region of cis-acting elements inhibiting transcription; iii) the expression of the reporter
gradually decreases when the sequence from -512 to -160 is progressively removed. These
results clearly demonstrate that the maximal luciferase activity is dependent on the -
512/+81 sequence (Figure 3, H construct), indicating the presence within this region of
positive regulatory elements, responsible for the maximum level of transcription activity.
In order to identify putative binding sites for transcription factors, computer-assisted
analysis of the sequences was performed. The -512/+1 region displays sequence homology
to the following transcription factor binding sites: USF1 (98%, Fig 4), AP-1 (88%),
GATA-1/3 (90-85%), NF-E2 (91%) and Sp1 (98-81%). We have previously reported the
interaction of Sp transcription factors to P1 promoter [16]; we therefore analyzed the other
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putative binding sites by EMSA, demonstrating that only the USF1 element is able to bind
nuclear extracts.
In vitro and in vivo Interaction of USF1 and USF2 transcription factors with the AβH-
J-J P1 promoter.
To determine whether the E-box site is able to interact with USF1 and USF2 transcription
factors, EMSA experiments were carried out using 2 µg of HeLa nuclear extracts and the
P1/USFmer probe (Table 1). The results obtained are reported in Figure 5 and indicate that
the P1/USFmer probe stably interacts with nuclear extracts, forming the complexes shown
in figure 5A (lane 1, arrows). As expected, P1/USFmer and consensus USFmer probes
efficiently compete with the binding (Figure 5A, lanes 2, 3), while Sp1mer and MyoDmer
probes do not (Figure 5A, lanes 4, 5). In order to demonstrate the presence of USF1 and
USF2 transcription factors in the retarded complexes, supershift analyses were performed.
We incubated P1/USFmer probe and 2 µg of nuclear extract from HeLa cells with
antibodies against USF1, USF2 or both factors (Figure 5B, lanes 7, 8 and 9 respectively).
Our results indicate that both antibodies induce a supershift of the retarded bands. These
data conclusively demonstrate that both USF1 and USF2 are able to bind to the
P1/USFmer probe in vitro.
In order to verify whether USF1/2 and P1 promoter interact in vivo, chromatin
immunoprecipitation (ChIP) assays were performed on HeLa cells. Chromatin was
immunoprecipitated using either USF1 and USF2 antiserum and quantitative amplification
of P1 promoter was performed on purified DNA. A representative ChIP assay (Figure 6A)
shows that amplification curves from samples immunoprecipitated with USF1 or USF2
antisera reach threshold 10 cycles early than those treated with MEF-2 antiserum or non
immune serum. In figure 6B ChIP results are reported as immunospecific fold enrichment
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in P1 promoter sequences relative to a negative control sequence that lacks USF1 binding
sites. The data supports the in vivo interaction between USF1 and USF2 and the P1
promoter in intact cells.
Mutation of the USF element of the AβH-J-J P1 promoter: effects on transcription.
Figure 7A-B shows the effect of the mutation of the P1/USFmer probe on its ability to bind
nuclear factors. 32P-labelled P1/USFmer (Figure 7A) or USFmer (Figure 7B) probes were
incubated with HeLa cell nuclear extract in the absence or in the presence of 100 fold
molar excess of competing wild type or mutant (P1/USFmut) oligonucleotides (see Table 1
for nucleotide sequences). The data obtained demonstrate that the mutations fully suppress
the ability of the probes to bind nuclear factors (Figure 7A, lane 2 and Figure 7B, lane 5).
The effect of this mutation on the transcription activity are shown in Figure 7C. The
reporter construct -512/+81 (H in Fig 3) was subjected to site directed mutagenesis in the
sequence spanning Sp1 and USF1 binding sites (constructs -512 P1/Spmut and -512
P1/USFmut). In addition a double mutant containing both mutations was generated (-512
P1/Sp+USFmut). HeLa cells were transfected with wild type -512/+81 (-512 WT), single
or double mutant AβH-J-J P1 promoter reporter constructs. Comparison of reporter
expression in HeLa extracts shows that the mutation in the USF binding site significantly
inhibits transcription directed by the -512 construct (Figure 7C). This effect is further
enhanced when the -512 P1/Sp+USFmut double mutant construct is employed. These data
strongly suggest that interaction of nuclear factors to the USF binding site is required for
maximum level of P1 promoter transcription.
Effect on P1 promoter activity of USF1 silencing obtained by RNA interference.
In order to demonstrate the role of proteins belonging to the USF family on the
transcription directed by the P1 promoter of the human AβH-J-J locus, silencing of the
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USF1 gene was performed using short interfering RNAs. A double stranded
oligonucleotide, targeting human USF1 RNA sequence, or a scrambled sequence (Table 2),
which has no significant homology to human genes and transcripts, were cloned into
pSingle-tTS-shRNA plasmid. HeLa cells were then transiently transfected with USF1
shRNA vector. To detect non-specific effects, scramble shRNA vector and construct
lacking small hairpin DNA (Null shRNA) were used as controls. Two days after
transfection, total RNA was extracted and used for quantitative Real Time RT-PCR, using
primers targeting USF1 mRNA or P1 promoter specific transcripts. Figure 8A shows that
USF1 mRNA levels are strongly reduced following transfection with USF1 shRNA vector.
In addition Figure 8B shows that USF1 depletion was associated with inhibition of the P1
directed transcription. The effects of null shRNA and scramble shRNA vectors were much
lower or absent on USF1 mRNA levels (Figure 8A) and P1 directed transcription (Figure
8B) respectively.
Discussion
The aim of the present paper is to investigate in detail one of the two promoter sequences
regulating the transcription of the AβH-J-J locus [14,15]. We isolated and identified the 5’-
flanking region of the exon 1 of this locus. The cloned nucleotide sequence allowed us to
characterize the P1 promoter region, which is involved in the regulation of AAH and
humbug expression. We have been able to identify transcripts relative to P1 promoter
activity in all tissues and cell lines analyzed [15, 16]. Similar to many housekeeping gene
promoters, the region under investigation lacks a TATA box and an initiator element [18].
In contrast, this sequence is GC-rich and presents homologies with Sp1 consensus binding
site, which we previously demonstrated to play a role in transcription [16]. Transfection
experiments with progressively deleted P1 promoter reporter constructs in HeLa cells
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showed that maximal promoter activity is located within 512 nucleotides from the principal
transcription initiation site (see Figures 3), a result which confirms our previous data in
HepG2 and RD cell lines [16]. Computer-assisted analysis of the -512/+1 region indicates
the presence of sequence homologies to binding sites for USF1, Sp1 and for other
transcription factors. EMSA analyses demonstrated no binding activity for these identified
elements with the exception of USF1 and Sp1 sites [16]. In the present study we analyzed
the DNA binding activity and function of USF transcription factors on P1 promoter.
The first conclusion of this manuscript derives from EMSA assays, supershift analysis and
chromatin immunoprecipitation assays, which coherently demonstrated that USF1 and USF2
factors bind to the P1/USF site of the P1 promoter, both in vitro (Figures 5) and in intact cells
(Figure 6).
The second conclusion is the demonstration that these interactions are functionally relevant for
transcription efficiency. The relevance of the USF binding for the transcription regulation of
the P1 promoter has been addressed by two complementary approaches: (a) mutagenesis of the
P1/USF element and (b) use of a USF1 silencing approach.
The results obtained concurrently demonstrate that USF transcription factors and USF1 binding
site are involved in the up-regulation of the P1 promoter of the human AβH-J-J gene locus. On
the other hand, mutagenesis experiments point out that the residual transcription activity of the
double mutant is compatible with the presence of other transcription factors participating in the
regulation of the P1 promoter. This is in agreement with previously published results from our
group [16] demonstrating the presence of at least 12 Sp binding sites and Sp1/3 dependent
transcription activity of P1 promoter. In addition, it is in agreement with the experiments on
progressively deleted reporter constructs indicating that the decrease of transcription associated
with the -512/-389 deletion is higher (Figure 3, - 42%) than that of the single mutant -512 P1/
USFmut construct with respect to the wild type plasmid (Figure 7, - 21%). This evidence
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coherently sustain the concept that other regulatory factors, in addition to USF, are involved in
P1 promoter directed transcription of the AβH-J-J locus.
When the results presented here are taken together with those recently published by Feriotto et
al. [16], it appears that both Sp and USF DNA interactions and transcription activities are
involved in the regulation of this human locus [19-23].
Comparison of the P1 and P2 promoter sequences of the AβH-J-J locus reveals important
differences are clearly detectable [15]. The most interesting result emerging from studies
focused on the P2 promoter is that the calcium–dependent transcriptional factor MEF-2
activates the transcription of junctin, junctate and AβH in striated muscles and brain [14].
Neither Sp1 nor USF binding sites were detected within the P2 promoter. On the other hand, P1
promoter, which drives the expression of AAH and humbug in most tissues, contains one USF1
and several Sp1 functionally active binding sites within the sequence having maximal
transcription activity [15, 16]. The finding that the sequences present in the upstream P1
promoter are significantly different from those of the P2 promoter is, in our opinion, of great
interest.
From the practical point of view, the impact of USF proteins in the transcriptional regulation of
this locus will be of future interest considering the potential contribution of AAH and humbug
to the infiltrating growth of neoplasms by increasing cell migration and enhancing proliferation
and survival [5-11]. For instance, overexpression of humbug and AAH is associated with
malignant progression in human gastric cancer cells [24]. In addition, relevant to our study,
Xian et al. found that the protein expression level of AAH in the hepatocellular carcinoma was
parallel with the mRNA expression level, indicating that the expression is regulated at the
transcription level [25]. Inhibition of AAH and humbug transcription could represent an
attractive approach for gene therapy of infiltrating tumors [3, 5]. Of course, in discussing the
possible implications of targeting mRNAs for USF transcription factor(s), careful
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considerations are required, due to a wide involvement of this transcription factor in the
regulation of expression of several genes, including genes involved in development and cell
cycle progression [17].
Conclusions
When the results shown in the present paper are considered together with previously published
reports by our research group, it can be concluded that the AβH-J-J locus contains at least two
functionally distinct promoters (P1 and P2), and multiple alternative splicing sites, leading to
the synthesis of the functionally distinct proteins, AAH, humbug, junctin, and junctate [1, 14-
16]. The P1 promoter directs AAH and humbug expression in most tissues and is up-regulated
by Sp and USF transcription factors.
Methods
Cell Cultures
The human hepatoblastoma, HepG2, breast cancer, MCF7 and MDA-MB231, cervix epithelial
carcinoma, HeLa, and embryonic kidney, Hek293, were cultured in E-MEM (Sigma, St. Louis,
MO, USA) supplemented with 2 mM L-glutamine (BioWhittaker, Walkersville, MD, USA)
and 1 mM sodium pyruvate (Sigma); embryonic rhabdomyosarcoma, RD cell line was cultured
in D-MEM ((BioWhittaker ) supplemented with 4 mM L-glutamine; melanoma, Colo 38, cell
line was cultured in RPMI 1640 (Sigma). All cell lines were grown in a humidified atmosphere
containing 5% CO2 at 37° C in medium supplemented with 100 units/ml penicillin, 100 µg/ml
streptomycin, and 10% (vol/vol) FBS.
Cell lines were all obtained from the ATCC (American Type Culture Collection, Manassas,
VA, USA).
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RT-PCR Real-time
Total RNA was harvested from cell lines by using the TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA). cDNA was synthesized from 0.5 µg of total RNA using ImProm-II™ (Promega,
Madison, WI, USA).
For quantitative real-time PCR reaction, 0,5/20 µl aliquots of cDNA, 10 pmol of E1f and E5r
primer (Table 1), 1 x iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA), were used
for each Sybr Green real-time PCR reaction to quantitate the relative expression of P1 specific
transcripts. Primer E1f and E5r were designed to amplify a 297 bp sequence present in all the
transcripts relative to P1 promoter activity and spanned intronic sequences in order to rule out
amplification from genomic DNA. Primers pairs and amplification conditions were validated
by melting curve and electhrophoretic analysis. Real-time PCR reactions were performed for a
total of 40 cycles (95°C for 10 s, 65°C for 30 s, and 72°C for 50 s) using an iCycler IQ® (Bio-
Rad). The relative proportions of each template amplified were determined by using IQ5
software (Bio-Rad), employing the ∆∆Ct method to compare gene expression data. Each
sample was quantitated in triplicate from at least two independent experiments. Mean ± S.D.
values were determined for each fold difference. Amplification of human Actin, GAPDH and
HMBS cDNA has been used as internal standards (housekeeping genes). Negative controls (no
template cDNA) were also run with every experimental plate to assess specificity and to rule
out contamination.
Transient transfection and dual luciferase assay
HeLa cells were transiently transfected with sequentially deleted reporter constructs, obtained
as previously described [16], containing different regions of the -661/+81 P1 nucleotide
sequence cloned into pGL3-basic reporter vector upstream firefly luciferase.
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Cells were seeded at 70-80% confluence in 16-mm wells. Transfection was performed after 24
hours using 1.2 µg of Lipofectamine 2000 (Invitrogen), 30 ng pRL-TK vector (Promega),
which contains the Renilla luciferase gene as a transfection efficiency control and 0.6 µg of
Firefly luciferase reporter plasmid per well. Lysates were prepared 48 h after transfection by
adding 100 µl of passive lysis buffer (Dual Luciferase Reporter Assay System, Promega).
Luciferase activity was determined with an analytical luminometer (model TD-20/20, Turner
Designs, Sunnyvale, CA, USA); the light intensity produced by Firefly luciferase (test plasmid)
was normalized to that produced by Renilla luciferase (control plasmid). Promoter activity was
expressed as fold induction relative to that of cells transfected with pGL3-basic vector [16].
Nuclear extract preparation
Nuclear extracts were prepared as described by Andrews and Faller [26]. Briefly, cells were
collected, washed twice with ice-cold phosphate-buffered saline, and resuspended in 0.4 ml/107
cells of hypotonic lysis buffer (10 mM Hepes/KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5
mM dithiothreitol, and 0.2 mM phenylmethanesulfonyl fluoride). After incubation on ice for 10
min, the mixture were vortexed for 10 seconds, and nuclei were pelleted by centrifugation at
12000 g for 10 seconds, then nuclear proteins were extracted by incubation of the nuclei for 20
min on ice with intermittent gentle vortexing in 20 mM Hepes/KOH, pH 7.9, 25% glycerol, 420
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM
phenylmethanesulfonyl fluoride, 1 µg·mL-1 aprotinin, 1 µg·mL-1 leupeptin, 2 mM Na3VO4, and
10 mM NaF (Sigma, St Louis, MO, USA); cell debris was removed by centrifugation at 12000
g for 5 min at 4 °C. The Bradford method was used to measure the protein concentration in the
extract, which was then stored in aliquots at -80 °C.
Electrophoretic mobility shift assays
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The double-stranded oligonucleotides (ODN) used in the EMSA are reported in Table 1. 3 pmol
of ODN were 32P-labeled using OptiKinase (GE Healthcare, Chalfont St Giles, UK), annealed
to an excess of complementary ODN and purified from [γ-32P]ATP (Perkin Elmer, Wellesley,
MA, USA). Binding reactions were performed by incubating 2 µg of nuclear extract and 16
fmol of 32P-labeled double-stranded ODN, with or without competitor in a final volume of 20
µL of binding buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 0.2 mM EDTA, 5
% glycerol, 1 mM dithiothreitol, 0.01 % TritonX100, 0.05 µg·µL-1 of poly dI-dC, 0.05 µg·µL-1
of a single-stranded ODN) [14]. Competitor (100 fold excess of unlabeled ODNs) and nuclear
extract mixture were incubated for 15 min and then probe was added to the reaction. After a
further incubation of 30 min at room temperature samples were immediately loaded onto a 6 %
nondenaturing polyacrylamide gel containing 0.25 x Tris/borate/EDTA (22.5 mM Tris, 22.5
mM boric acid, 0.5 mM EDTA, pH 8) buffer. Electrophoresis was carried out at 200 V. Gels
were vacuum heat-dried and subjected to autoradiography. Supershift assays were performed as
described previously [16] by using 2 µg of commercially available antibodies specific for USF1
(sc-229X) and USF2 (sc-862X) transcription factors (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA).
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation assays were performed by using the Chromatin
Immunoprecipitation Assay Kit (Upstate Biotechnology Inc., Lake Placid, NY, USA). Briefly,
a total of 6 x 107 HeLa cells (from 5 15-cm plates) were treated, for 10 min at room
temperature, with 1% formaldehyde culture medium. Cells were washed in phosphate-buffered
saline, and then glycine was added to a final concentration of 0.125 M. The cells were then
suspended in 1.5 ml of lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-Cl, pH 8.1) plus
protease inhibitors (1 µg/ml pepstatin A, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 mM
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phenylmethylsulfonyl fluoride) and the chromatin subjected to sonication (using a Sonics
Vibracell VC130 sonicator with a 2-mm probe). Fifteen 15-s sonication pulses at 30%
amplitude were required to shear chromatin to 200-1000 bp fragments. 0.2-ml aliquots of
chromatin were diluted to 2 ml in ChIP dilution buffer containing protease inhibitors and then
cleared with 75 µl of salmon sperm DNA/protein A-agarose 50% gel slurry (Upstate
Biotechnology) for 1 h at 4°C before incubation on a rocking platform with either 6-10 µg of
specific antiserum USF1, USF2, and MEF-2A (Santa Cruz Biotechnology) or normal rabbit
serum (Upstate Biotechnology). 20 µl of diluted chromatin was saved and stored for later PCR
analysis as 1% of the input extract). Incubations occurred overnight at 4 °C and continued an
additional 1 h after the addition of 60 µl protein A-agarose slurry. Thereafter the agarose pellets
were washed consecutively with low salt, high salt and LiCl buffers. DNA/protein complexes
were recovered from the pellets with elution buffer (0.1 M NaHCO3 with 1% SDS), and cross-
links were reversed by incubating overnight at 65 °C with 0.2 M NaCl. The samples were
treated with RNase A and proteinase K, extracted with phenol/chloroform and ethanol-
precipitated. The pelletted DNAs were washed with 70% ethanol and dissolved in 40 µl of
Tris/EDTA. 2 µl aliquots were used for each real-time PCR reaction to quantitate
immunoprecipitated promoter fragments.
Real-time PCR Quantitation of Immunoprecipitated Promoter Fragments
For quantitative real-time PCR reaction conditions each 25 µl reaction contained 2 µl of template
DNA (from chromatin immunoprecipitations), 10 pmol of primers (Table 1) and 1 x iQ™
SYBR® Green Supermix (Bio-Rad). Real-time PCR reactions were performed for a total of 40
cycles (97°C for 15 s, 65°C for 30 s, and 72°C for 30 s) using an iCycler IQ® (Bio-Rad). The
relative proportions of immunoprecipitated promoter fragments were determined based on the
threshold cycle (Tc) value for each PCR reaction. Real time PCR data analysis followed the
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methodology previously described [27,28]. A ∆TC value was calculated for each sample by
subtracting the Tc value for the input (to account for differences in amplification efficiencies and
DNA quantities before immunoprecipitation) from the Tc value obtained for the
immunoprecipitated sample. A ∆∆Tc value was then calculated by subtracting the ∆Tc value for
the sample immunoprecipitated with specific antiserum from the ∆Tc value for the
corresponding control sample immunoprecipitated with nonimmune rabbit serum. Fold
differences (specific antiserum ChIP relative to nonimmune serum control ChIP) were then
determined by raising 2 to the ∆∆TC power. PCR was also performed using control primers that
amplify a 197 bp genomic region lacking USF1 binding sites. The ∆∆Tc values were then
calculated as previously described and the negative control PCR data were used to normalize
quantitative results from different immunoprecipitation. Each sample was quantitated in
triplicate on at least two separate experiments and from at least two independent
immunoprecipitations. Mean ± S.D. values were determined for each fold difference.
Site-directed mutagenesis
Mutagenesis was performed by using a QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA). Two double stranded mutant oligonucleotides (P1/Spmut and P1/USFmut
plus the flanking 9-12mer of P1 nucleotide sequence (Table 1) were used to inactivate specific
binding in the pGL3 construct containing the -512/+81 promoter sequence. The nucleotide
sequence of the mutant constructs was confirmed by DNA sequencing.
USF1-targeted shRNA plasmid construction and transfection in HeLa cells
The effect of USF1 on P1 promoter directed expression was evaluated by RNA interference
approach using the KnockoutTM Single Vector Inducible RNAi System (Clontech, Mountain
View, CA, USA). siRNA targeting USF1 mRNA (GenBank accession n° NM_007122) were
designed by using the siRNA-sequence designer software (Clontech). We produced a double
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strand oligonucleotide for shRNA plasmid construction containing from 5’ to 3’ end: XhoI
cloning site, a guanine residue, the 19 base pair target specific sense strand followed by a short
spacer (TTCAAGAGA), the reverse complement of the sense strand, six thymidines, as an RNA
polymerase III transcription stop signal, a HindIII cloning site (Table 2). This oligonucleotide
was cloned into XhoI-HindIII site of the pSingle-tTS-shRNA Vector (Clontech), in which
shRNA is expressed under the control of the U6 promoter. A negative control scrambled siRNA,
which had no significant homology to human gene and transcript sequences, was designed to
detect any non specific effects.
After cloning and sequence characterization, 500 ng of plasmids were transfected into HeLa cells
using Lipofectamine 2000 (Invitrogen), and, after 8 hours, 20 ng/ml of doxycycline were
added. Fourty-eight hours later RNA extraction and reverse transcription were performed. To
quantitate the depletion of USF1 and AβH-J-J P1 directed transcripts, 1/20 µl aliquots of cDNA
and 10 pmol of the primers reported in table 1 were used for each Sybr Green real-time PCR
reaction. Resuls were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and hydroxymethylbilane synthase (HMBS) expression levels (housekeeping genes). Real-time
PCR reactions were performed for a total of 40 cycles (95°C for 10 s, 66°C for 30 s, and 72°C
for 50 s). The ∆∆Ct method was used to compare gene expression data.
Statistical analysis
All the data were normally distributed and presented as mean ± S.D. Statistical differences
between groups were compared using one-way ANOVA (ANalyses Of VAriance between
groups) software. Statistical significance was assumed at p < 0.05.
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Tables
Table 1. Sequence of synthetic oligonucleotides used in this study
Double-stranded oligonucleotides used in gel shift assays and mutagenesys a
P1/USFmer 5'-GGCGGCCCACGTGTCCACCT-3'
USFmerb 5'-GGCCAGACCACGTGGTCTGTTC-3'
Sp1merb 5'-CCCTTGGTGGGGGCGGGGCCTAAGCTGCG-3'
MyoDmerc 5'-CCCCCCAACACCTGCTGCCTGA-3'
P1/USFmut 5'-CCCACGGGCGGCCACAGTGTCCACCTATTC-3'
P1/Spmut 5'-GTGAGCATAGTCGTAGAGCATGGTAGAGTACCGC-3'
Q-PCR Primers Amplified region Sequences
P1 ChIP f P1 promoter AβH-J-J 5'-AACGAACTAAATTCCTGCTTCAGC-3'
P1 ChIP r (contains USF elements) 5'-TCCTTTGGAACGTGGCAAACGT-3'
Neg ChIP f negative control region 5'-TGTGTGATTTCCCGTCAACTGTC-3'
Neg ChIP r (without USF elements) 5'-CCAGCCTCTTCCATTGGATACAA-3'
E1 f from exon 1 to 5 5'-CAAGAGCAGCGGCAACAG-3'
E5 r of AβH-J-J transcripts 5'-AATAAAACTTTGGCATCATCCACTCAAAATCTCC-3'
qUSF1 f 5'-TGATGATGCAGTTGACACGGA-3'
qUSF1 r
USF1 transcripts
5'-CAGTTGTTGATCTTGTCTCGGC-3'
GAPDH f glyceraldehyde-3-phosphate 5'-AAGGTCGGAGTCAACGGATTT-3'
GAPDH r dehydrogenase mRNA 5'-ACTGTGGTCATGAGTCCTTCCA-3'
HMBS f hydroxymethyl-bilane 5'-GAACATGCCCTGGAGAAGAATGA-3'
HMBS r synthase mRNA 5'-GGTAGCCTGCATGGTCTCTTGTAT-3'
ACTIN f 5'-TGACGGGGTCAACCACACTGTGCCCATCTA-3'
ACTIN r
actin mRNA
5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3'
a Nucleotide mutations are underlined; bThe oligonucleotide containing USF1 and Sp1sites were purchased from Geneka;
c [14].
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Table 2. Double stranded oligonuleotides sequences inserted in shRNA vectors
USF1 shRNA
5'-TCGAGGTCGACAACAGGTGGAAGATTTCAAGAGAATCTTCCACCTGTTGTCGACTTTTTTACGCGTA-3'
3'-CCAGCTGTTGTCCACCTTCTAAAGTTCTCTTAGAAGGTGGACAACAGCTGAAAAAATGCGCATTCGA-5'
Scramble shRNA
5'-TCGAGGTACCGAACAACGCAACGAATTCAAGAGATTCGTTGCGTTGTTCGGTACTTTTTTACGCGTA-3'
3'-CCATGGCTTGTTGCGTTGCTTAAGTTCTCTAAGCAACGCAACAAGCCATGAAAAAATGCGCATTCGA-5'
The 19 base pair oligonucleotides specific for USF1 siRNA or containing scambled sequences are underlined;
XhoI and HindIII cloning sites are in italic.
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Figure legends
Figure 1 - Structure of the 5' end of the human locus for AAH, humbug, junctate,
and junctin.
Arabic numbers over black boxes indicate exons. Intervening sequences are indicated in
Roman numbers. The two putative promoters P1 and P2 are indicated. A schematic
representation of AAH, humbug, junctate and junctin exons splicing is reported at the
bottom of the panel. The cytoplasmic, TM, positively charged, calcium-binding, and
catalytic domains are indicated. The locations of AUG, stop codons, and poly(A) signals
are shown.
Figure 2 - Quantitative Real-time RT-PCR analysis of the transcripts starting from
P1 promoter in human cell lines.
(A) The exon 1 starting mRNAs of AAH and humbug, the PCR primers and the 297 bp
PCR product are represented; white boxes indicate exons common to the two transcripts.
(B) Relative mRNA expression levels of P1 promoter transcripts were evaluated by
Quantitative real-time RT-PCR in which cDNA derived from human cell lines (a, MCF7;
b, Colo 38; c, Hek293; d, HepG2; e, HeLa; f, RD; g, MDA) total RNA were amplified.
Relative quantification is expressed as normalized fold expression and was calculated by
using MCF7 as reference sample (value = 1). All data represent the mean of three
determinations from two independent experiments; *P < 0.001.
Figure 3 - AβH-J-J P1 promoter activity in HeLa cell line.
HeLa cells were transiently transfected with sequentially deleted reporter constructs of the
-661/+81 P1 nucleotide sequence (represented in the left side of the figure, F-M).
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Transient transfection and luciferase assays were performed in triplicate, and the data
(right side of the figure) were normalized to renilla luciferase activity and are shown as
relative activities compared to that for pGL3-basic, a reporter vector with a basal promoter.
The values are the means ± SD of at least three independent experiments.
Figure 4 - DNA sequence of the AβH-J-J P1 promoter region.
(A) -512/+112 P1 promoter and 5’ UTR sequences. Solid line indicate the oligonucleotide
used in EMSA (Table 1). Sequence homologies to USF and Sp1 transcription factor
binding site are boxed; the percent of homology was obtained by TF SEARCH ver. 1.3.
Arrows indicate the characterized transcription initiation sites (arrow thickness is
proportional to transcription start activity) [16]. The nucleotide deletions of reporter
constructs are shown in grey.
Figure 5 - Interaction of USF1 and USF2 transcription factors with the AβH-J-J P1
promoter.
(A) EMSA were carried out on 2 µg of Hela nuclear extracts as described in the
Experimental procedures using P1/USFmer probe (Table 1). Probe was incubated with
nuclear extracts in the absence of competing oligonucleotides (lane 1) or in the presence of
the indicated competing oligonucleotides (lanes 2-5). Arrows and asterisk indicate the
specific and non-specific complexes respectively. (B) Supershift assay was performed
using P1/USFmer probe and 2 µg of nuclear extract from HeLa cells; probe was incubated
with nuclear exctract in the absence of antibody (lane 6) or in the presence of antibodies
against USF1 factor, USF2 factor or both (lanes 7, 8, and 9 respectively). Arrows indicate
the specific complexes and arrowheads indicate the super-shifted complexes.
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Figure 6 - Chromatin immunoprecipitation assay performed to evaluate in vivo USF
interaction with P1 promoter.
(A) Representative quantitative real-time PCR profiles for the amplification of the P1
promoter in the ChIP assay. USF1 ChIP, USF2 ChIP and MEF-2A ChIP represents
duplicate amplification curves from chromatin immunoprecipitated with USF1, USF2 or
MEF-2A antiserum respectively; nonimmune serum represent curves from
immunoprecipitations with nonimmune rabbit serum. Input represents curves obtained
from HeLa chromatin (1%) before immunoprecipitation. TF, threshold fluorescence. (B) In
vivo association of USF1 and USF2 transcription factors with the AβH-J-J P1 promoter.
The results, obtained from ChIP assay quantitative real time PCR using USF1 (USF1
ChIP) or USF2 (USF2 ChIP) antiserum, were analyzed following the methodology
described in the methods section. The fold increase over negative control PCR in each case
compares the values obtained by P1 promoter amplification to the corresponding
amplification of a distal genomic region lacking USF1 binding sites (Table 1). All data
represent the mean of two separated PCR experiments each performed in triplicate, and
obtained from at least two independent immunoprecipitation. The asterisk indicates that the
value is significantly different (p < 0,05) from the control value.
Figure 7 - Mutational analysis of USF elements in the AβH-J-J P1 promoter.
(A) EMSA were performed incubating P1/USFmer probe with 2 µg of nuclear extract from
HeLa cells in the absence (lane 1) or in the presence of 100 fold molar excess of the
indicated competing oligonucleotides (lanes 2-3). (B) USFmer probe was incubated with 2
µg of nuclear extract from HeLa cells in the absence (lane 4) or in the presence of 100 fold
molar excess of the indicated competing oligonucleotides (lanes 5-7) (Table 1). Arrows
and asterisks indicate the specific and aspecific complexes respectively. (C) The reporter
construct -512 WT (H in Fig 3) was subjected to site directed mutagenesis in the sequence
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spanning Sp1 and USF binding sites. The constructs obtained were designated as -512
P1/Spmut and -512 P1/USFmut. In addition a double mutant containing both mutations
was indicated as -512 P1/Sp+USFmut. HeLa cells transient transfection and luciferase
assay were performed in two experiments conducted in triplicate and the data were
normalized to Renilla luciferase activity and reported as ratios (means ± SD) to the wild
type reporter construct -512 WT; *P < 0.05 and **P < 0.02.
Figure 8 - Effect of USF1 silencing obtained by short interference RNA on P1
promoter activity.
HeLa cells were transiently transfected with USF1 shRNA vector, with Scramble shRNA
vector or vector in which no small hairpin DNA oligo was cloned (Null shRNA vector).
Two days after transient transfection of these vectors into HeLa cells, total RNA was
extracted and used for quantitative Real Time RT-PCR, using primers targeting USF1
mRNA (panel A) or P1 promoter specific transcripts (panel B). Results represent the
average ± SD of three independent experiments carried out in duplicate; ∆∆Ct method was
used to compare gene expression data, standard error of the mean was calculated; statistical
significance: *P < 0.05.
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